Skip to main content

Scrotal Botulinum Toxin A Injection ("Scrotox")

Scrotal BoNT/A injection ("Scrotox") is the off-label subdermal injection of onabotulinumtoxinA into the scrotal dartos smooth muscle to induce temporary chemical relaxation, producing a smoother, more pendulous, less rugated scrotum. The procedure is entirely off-label — onabotulinumtoxinA carries no FDA-approved scrotal indication.[1][2] Unlike surgical reduction scrotoplasty, which removes skin to tighten the envelope, Scrotox relaxes the dartos to elongate and smooth it; the two procedures serve opposite aesthetic preferences and are not interchangeable.

For the broader male cosmetic decision framework see the Male Cosmetic Genital Surgery atlas page; for the surgical alternative see Reduction Scrotoplasty.

Mechanism of Action​

General BoNT/A. Heavy-chain binding → endocytosis → light-chain cleavage of SNAP-25 → impaired SNARE-mediated synaptic vesicle fusion → blocked acetylcholine release → chemical denervation.[3][4] Beyond skeletal muscle, BoNT/A blocks efferent autonomic fibers to smooth muscle and exocrine glands.[5]

Scrotal dartos pharmacology (Gibson 2002).[6]

  • Receives a functional sympathetic (α-1 adrenergic) innervation; contracts to noradrenaline.
  • No functional inhibitory innervation — relaxation is passive.
  • Profoundly thermosensitive: contractile response at 30 °C is reduced by ~80% at 40 °C, mediated by myosin phosphatase.
  • Does not respond to carbachol, nicotine, histamine, serotonin, or substance P.

Implication. Because the dartos is noradrenergic, BoNT/A's effect is most plausibly indirect — preganglionic sympathetic acetylcholine blockade or effects on sensory / autonomic terminals — analogous to detrusor and sphincter applications.[4][5] The exact dartos mechanism has not been specifically elucidated.

Clinical Applications​

1. Aesthetic scrotal relaxation ("Scrotox") — the primary use​

Mehdizadeh 2026 SR/meta-analysis included scrotal relaxation among nonfacial off-label aesthetic BoNT/A uses; overall satisfaction across all off-label aesthetic applications was 94% (95% CI 88–98%) with sustained results in 75% at first follow-up.[1] Stated aesthetic goals:

  • Smoother scrotum (reduction of rugae).
  • Lower-hanging scrotum (dartos relaxation allows more elongation).
  • Reduced cold / stress retraction.
  • Perceived increase in scrotal size.

2. Penile retraction (penile dartos) — proof of concept (Shaeer 2009)[7]​

  • 10 men with short flaccid penis but normal erect and outstretched length.
  • 100 U onabotulinumtoxinA into the penile dartos.
  • 70% subjectively reported decreased frequency and amplitude of retraction with improved flaccid length; clinical measurement showed less retraction rather than added length.
  • Effect completely faded by month 6; no side effects.

3. Chronic scrotal pain — spermatic cord block (not dartos)​

  • Khambati 2014 (open-label pilot, n = 18, 100 U): 72% pain reduction at 1 mo (VAS 7.36 → 5.61, p < 0.003).[8]
  • Dockray 2020 RCT (n = 64, 200 IU vs local anesthesia alone): no statistically significant difference; open-label crossover suggests a placebo effect.[9]

Bottom line: BoNT/A cord block is not superior to local anesthesia alone for chronic scrotal pain.

4. Cremasteric synkinesia / spasm (Mori 2011)[10]​

100 U in 10 mL saline per injection × 3, 6 weeks apart; pain 8/10 → 3/10 after first injection; peak at 2 wk, dissipation at 4–6 wk; baseline 2–4/10 after three injections.

Injection Technique (Aesthetic)​

Dose. Practice-based: 50–100 U onabotulinumtoxinA, typically reconstituted as 100 U in 2–4 mL saline.[1][7]

Injection points.

  • Scrotal skin is thin; dartos sits immediately beneath — straightforward subdermal placement.
  • 4–8 sites per hemiscrotum distributed across the anterior and lateral surfaces.
  • Avoid the median raphe and posterior scrotum to minimize risk to scrotal-septum nerves and perineal structures.
  • Topical anesthetic or ice for patient comfort.

Onset and duration.

PhaseTiming
Onset~3–7 days
Peak effect2–4 weeks
Effective relaxation~3–4 months
Complete fade~6 months (extrapolated from Shaeer penile-dartos data)

Repeat injections required to maintain effect.

Dose comparison across genital BoNT/A applications​

ApplicationDoseDilutionTargetDuration
Penile dartos (Shaeer 2009)100 U onabotulinumtoxinANot specifiedPenile dartos~6 mo (complete fade)[7]
Scrotal aesthetic (practice-based)50–100 U100 U in 2–4 mL salineScrotal dartos~3–4 mo[1]
Cord block for CSP100–200 UIn salineSpermatic cord~3 mo (pain)[8][9]
Cremasteric injection (Mori 2011)100 U per session100 U in 10 mL salineCremaster4–6 wk per injection[10]

Outcomes Summary​

ApplicationDesignnResponseDuration
Penile dartos relaxation[7]Open-label prospective1070% subjective~6 mo
Off-label aesthetic (all sites)[1]SR / meta-analysis1,90394% satisfaction, 75% sustained at first follow-upVariable
CSP cord block (open-label)[8]Pilot1872% at 1 mo (VAS 7.36 → 5.61)~3 mo
CSP cord block (RCT)[9]Double-blind RCT64No superiority vs local anesthesia—
Cremasteric spasm[10]Case report1Pain 8 → 3 / 104–6 wk per injection

Safety — The Fertility Signal​

Breikaa 2014 (mature rats).[13] Intracremasteric BoNT/A 10 / 20 / 40 U/kg × 3 (2-week intervals):

  • Inhibited spermatogenesis on flow cytometry.
  • Histopathology: seminiferous tubules separated by dense fibers (dose-dependent).
  • Altered LDH-X and acid phosphatase activity.
  • Authors: "Decreased fertility may be a serious problem Botox injections could cause."

Breikaa 2016 (immature / growing rats).[14] Confirmed decreased sperm count and quality, delayed maturation on flow cytometry, and significantly increased apoptosis markers — apoptosis-mediated mechanism.

Caveats.

  • Animal doses (10–40 U/kg) are much higher relative to body weight than typical aesthetic human doses.
  • Intracremasteric injection places toxin closer to the testis than subdermal scrotal dartos placement.
  • No human studies have specifically evaluated fertility after scrotal dartos BoNT/A injection.
  • DAXXIFY (daxibotulinumtoxinA) FDA label notes reduced rat fertility at doses associated with paternal toxicity; no effect at ~4× MRHD.[15]

Thermoregulatory concern. Gibson's data show the dartos is the principal thermosensor / effector of scrotal cooling. Chemical paralysis would theoretically blunt cold-induced contraction and disrupt countercurrent heat exchange, with potential effects on the 2–4 °C testicular-below-core gradient required for spermatogenesis — plausibly contributing to the Breikaa observations.[6][13] No human studies have measured testicular temperature after Scrotox.

Other complications. Injection-site bruising / hematoma (highly vascular dartos), pain, asymmetric relaxation, over-dosing producing an uncomfortably pendulous scrotum, and diffusion to cremaster / cord / perineal muscles.

Scrotox vs Surgical Reduction Scrotoplasty​

FeatureScrotox (BoNT/A)Reduction scrotoplasty
MechanismDartos relaxation (chemical)Skin excision ± rearrangement
Aesthetic directionElongation / smoothingTightening / reduction
DurationTemporary (3–6 mo)Permanent
InvasivenessInjection onlySurgical excision
AnesthesiaTopical / noneLocal cord block ± sedation
RecoveryMinimal2–4 wk activity restriction
RepeatEvery 3–6 moNot typically needed
Cumulative costHigh (repeat)One-time
Fertility concernTheoretical (animal data)None
RegulatoryOff-labelEstablished (CPT 55175 / 55180)

The two procedures address opposite aesthetic preferences — they are complementary in the menu, not interchangeable.

Regulatory and Counseling​

  • Off-label for any scrotal indication.[2]
  • Evidence level — Level V (expert opinion + extrapolation from Shaeer penile-dartos + inclusion in off-label SRs). No dedicated trial of aesthetic scrotal BoNT/A.
  • Informed consent must cover: off-label status, temporary effect, repeat-treatment requirement, theoretical fertility risk (cite Breikaa animal data), thermoregulatory disruption, and absence of human safety data.
  • Reproductive-age men should receive explicit fertility counseling before proceeding.

Current Standing​

Scrotal BoNT/A is a growing but poorly studied aesthetic procedure. The Mehdizadeh 2026 SR/meta-analysis recognizes scrotal relaxation among off-label aesthetic uses with strong overall satisfaction across the broader off-label-aesthetic literature, but calls for standardized protocols and refined evaluation methods. There are no dedicated clinical trials, no standardized scrotal-specific dosing protocol, no long-term safety data, and no human fertility studies. The Breikaa animal data constitute an unaddressed safety signal.[1][13][14]

See Also​

References​

1. Mehdizadeh M, Shariati K, Cordero JJ, et al. Beyond wrinkles: a systematic review and meta-analysis of off-label aesthetic uses of botulinum neurotoxin. Ann Plast Surg. 2026;96(4S Suppl 4):S124–S133. doi:10.1097/SAP.0000000000004662

2. US Food and Drug Administration. Orange Book — onabotulinumtoxinA approved indications.

3. Brin MF, Burstein R. Botox (onabotulinumtoxinA) mechanism of action. Medicine (Baltimore). 2023;102(S1):e32372. doi:10.1097/MD.0000000000032372

4. Kumar R, Dhaliwal HP, Kukreja RV, Singh BR. The botulinum toxin as a therapeutic agent: molecular structure and mechanism of action in motor and sensory systems. Semin Neurol. 2016;36(1):10–19. doi:10.1055/s-0035-1571215

5. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3–9. doi:10.1159/000083259

6. Gibson A, Akinrinsola A, Patel T, et al. Pharmacology and thermosensitivity of the dartos muscle isolated from rat scrotum. Br J Pharmacol. 2002;136(8):1194–1200. doi:10.1038/sj.bjp.0704830

7. Shaeer O, Shaeer K, Shaeer A. Botulinum toxin A (Botox) for relieving penile retraction. J Sex Med. 2009;6(10):2788–2794. doi:10.1111/j.1743-6109.2009.01434.x

8. Khambati A, Lau S, Gordon A, Jarvi KA. OnabotulinumtoxinA (Botox) nerve blocks provide durable pain relief for men with chronic scrotal pain: a pilot open-label trial. J Sex Med. 2014;11(12):3072–3077. doi:10.1111/jsm.12707

9. Dockray J, Aljumaily A, Lau S, Jarvi KA. A randomized, double-blind, controlled trial shows that onabotulinumtoxinA nerve blocks do not provide improved pain control in men with chronic scrotal pain. J Urol. 2020;203(4):767–772. doi:10.1097/JU.0000000000000658

10. Mori R, Vasavada S, Baker D, Sabanegh E. Treatment of debilitating cremasteric synkinesia with intracremasteric botulinum-A toxin injections. Urology. 2011;78(1):214–216. doi:10.1016/j.urology.2011.03.011

11. Dashtipour K, Pedouim F. Botulinum toxin: preparations for clinical use, immunogenicity, side effects, and safety profile. Semin Neurol. 2016;36(1):29–33. doi:10.1055/s-0035-1571213

12. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65–69. doi:10.1159/000370245

13. Breikaa RM, Mosli HA, Nagy AA, Abdel-Naim AB. Adverse testicular effects of Botox in mature rats. Toxicol Appl Pharmacol. 2014;275(2):182–188. doi:10.1016/j.taap.2014.01.003

14. Breikaa RM, Mosli HA, Abdel-Naim AB. Influence of onabotulinumtoxinA on testes of the growing rat. J Biochem Mol Toxicol. 2016;30(12):608–613. doi:10.1002/jbt.21828

15. US Food and Drug Administration. DAXXIFY (daxibotulinumtoxinA-lanm) label.

16. Thomas C, Navia A. Aesthetic scrotoplasty: systematic review and a proposed treatment algorithm for the management of bothersome scrotum in adults. Aesthet Plast Surg. 2021;45(2):769–776. doi:10.1007/s00266-020-01998-3